Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Laser Therapy for Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is at least 18 years of age at screening, but has not had their 66th birthday.~* SCID diagnosis of major depressive disorder (Structured Clinical Interview for Diagnostic Statistical Manual-IV)~* HAM-D-17 \>14 and \< 25~* Women of child-bearing potential must use a double-barrier method for birth control (e.g. condoms with spermicide) if sexually active.~* Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study.~* The subject (and caregiver, if applicable) is willing to participate in this study for at least 8 weeks.~* Subjects on an antidepressant will need to be on a stable dose for at least six weeks.~Exclusion Criteria:~* The subject is pregnant or lactating.~* The subject failed two or more FDA-approved antidepressants during current episode~* Subjects with less than 2 months MDD symptom free prior to current episode.~* The subject used targeted psychotherapies for depression during current episode (support therapy or counseling are allowed)~* Substance dependence or abuse in the past 6 months~* Psychotic disorder or psychotic episode (current psychotic episode per SCID assessment)~* Bipolar affective disorder (per SCID assessment)~* Unstable medical illness, defined as any medical illness which has not been well-controlled with standard-of-care medications (e.g., insulin for diabetes mellitus, HCTZ for hypertension)~* Active suicidal or homicidal ideation, as determined by CHRT screening~* The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be directly below any of the procedure sites.~* The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolised AVM, implantable shunt - Hakim valve).~* Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (in US: Visudine (verteporfin) - for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TLT Treatment Group 1 (Type: EXPERIMENTAL): The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
- TLT Treatment Group 2 (Type: SHAM_COMPARATOR): The sham group will receive 2 treatments of the sham device per week for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).